Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

ZO Skin Health

Also known as: zo, zo skincare, zo skin health, zo medical

ZO Skin Health, Inc. is a US physician-dispensed skincare brand founded in 2007 by dermatologist Zein Obagi and majority-owned by Blackstone since 2020. It is a separate company from Obagi Medical. Its US range has included prescription-only hydroquinone and tretinoin products; its UK range is cosmetic.

Evidence status

Manufacturer-supported

Named ZO products appear in two uncontrolled Japanese combination series that reported improvement but bundled the topicals with lasers, prescription agents or oral treatment, so their contribution cannot be isolated. A 2026 acne study is uncontrolled and co-authored by ZO's founder; no indexed randomised trial of a named ZO product was located. Nu-Derm trials concern a separate company and cannot be transferred to ZO Skin Health.

What ZO Skin Health is, and the ranges available#

ZO Skin Health, Inc. is a California professional skincare company founded in 2007 by Dr Zein Obagi. Blackstone acquired a majority interest in October 2020.[8]

ZO and Obagi Medical are separate companies. Obagi Medical traces to 1988 and launched Nu-Derm; Dr Obagi ceased owning its shares in 2010. The companies litigated and settled in 2011, with Obagi Medical paying the ZO parties US$5 million and granting limited trademark rights.[5][5]

The UK entity, ZO Skin Health Limited, company 13395730, was incorporated in May 2021 as Wigmore Aesthetics Limited and renamed that September. Its recorded controlling shareholder was ZO SH Holdings Inc of Delaware.[4]

The UK site sells cleansers, exfoliators, toners, retinols, targeted cosmetics, peels, masques, sunscreens and moisturisers directly and through authorised providers. It carries no prescription, hydroquinone or tretinoin category.[7]

Archived US material includes a 4% hydroquinone Pigment Control programme marked Rx and tretinoin USP 0.05% and 0.1% creams described as physician-only and prescription-only. The ZO 3-Step Peel is a separate professional system containing salicylic, TCA and lactic acids, a retinol cream and a hydrating cream; its published lists contain no hydroquinone.[6]

Use of ZO Skin Health in aesthetic practice#

UK ZO retail products are cosmetics. In GB, hydroquinone is prohibited in cosmetic skin products under Annex II entry 1339, with its only cosmetic exception being 0.02% after mixing in professional artificial-nail systems.[1]

Hydroquinone is not prohibited as a medicine, but no hydroquinone-containing product appears in the electronic Medicines Compendium. Access to 4% hydroquinone therefore requires a prescriber accepting responsibility for an unlicensed medicine. It is never a cosmetic retail transaction.[1, 2][3]

Topical tretinoin is a prescription-only medicine. It may be supplied only on an appropriate prescription; the emc lists it in combination topicals and oral products, not as a single-agent cream. An aesthetician, beauty therapist or non-prescribing nurse cannot supply ZO's US hydroquinone or tretinoin items.[2, 3][3][1, 2]i

Professional or physician-dispensed branding does not alter these rules. The US and UK catalogues differ, and an American product page or FDA status has no British legal force.[6, 7]

The ZO 3-Step Peel sits within chemical-peel competence and the current manufacturer directions. England's licensing model remains proposed rather than in force; prescription supply law applies regardless of any future procedural licence.

Contraindications and cautions#

The exact ZO product governs. A cosmetic retinol, TCA/salicylic/lactic peel, prescription tretinoin and unlicensed hydroquinone cream have different legal status, contraindications and clinical oversight.

Any proposed hydroquinone or tretinoin use requires a named prescriber, lawful supply and a prescription-specific consultation. Existing prescription regimens are not altered by an aesthetic practitioner.

The 3-Step Peel is labelled professional-only and, in US material, restricted to a licensed physician or trained specialist under physician supervision. Its active acids and retinol require product-specific screening and cannot be reduced to a general ZO protocol.[6]

Pigment treatment also requires diagnosis. Melasma, PIH, lentigines, exogenous ochronosis and suspicious lesions do not share one pathway.

Clinical uses and the evidence behind them#

ZO combination programmes

The largest ZO-naming series prospectively followed 251 Asian patients in Japan; 227 completed a programme combining ZO topicals with Q-switched alexandrite and carbon-dioxide lasers. Outcomes were excellent in 97, good in 113, fair in 17 and poor in none, with adverse events in 3.2%. There was no control or topical-only arm.[9]

A second retrospective Japanese series included 27 people, with six completing a combination of oral tranexamic acid, vitamins C and E, ZO hydroquinone creams, Obagi tretinoin 0.1% and Q-switched laser. Blinded mean MASI fell from 19 to 2.8 (p=0.0054). This is a positive multi-treatment result, not evidence for ZO alone.[14]

A 2026 uncontrolled study in 40 people with moderate-to-severe acne reported reductions of 68.6% in inflamed pustules, 92.2% in nodules, 32.3% in PIH and 52% in Cutibacterium acnes at 12 weeks with a retinol and site-specific salicylic-acid system. ZO's founder was an author and the abstract did not name the marketed product.[10]

Evidence belonging to Obagi Medical

A 36-woman investigator-blinded comparison found a four-product hydroquinone-free regimen and seven-product hydroquinone-containing Obagi Nu-Derm both improved several pigmentation and photoageing outcomes at 12 weeks with no significant group difference, apart from tactile roughness.[12]

A 56-woman double-blind trial around laser or peel treatment found Nu-Derm did not improve re-epithelialisation or pigment outcomes versus standard care; preoperative erythema was higher after Nu-Derm. Obagi Medical funded the study.[11]

These trials inform hydroquinone systems or Obagi Medical. They are not ZO formulation trials. Reports of depigmentation and paradoxical hyperpigmentation after Nu-Derm and Reverse likewise describe hydroquinone-containing branded systems, not the UK ZO cosmetic catalogue.[13]

Selecting a ZO Skin Health product#

Selection starts with market and legal category. The current UK pack identifies a cosmetic; archived US “Rx” material cannot be imported conceptually into a UK retail recommendation.[6, 7]

For cosmetics, ingredient list, active form, concentration where disclosed, formulation, intended use and current directions matter. For the 3-Step Peel, the exact manufacturer protocol, depth, training and insurance govern. Skinipedia does not publish a substitute.

Product evidence must name the product. ZO combination series cannot isolate the topical, the acne abstract may not identify a marketed SKU, and Nu-Derm trials belong to Obagi Medical. No study establishes that a ZO formulation outperforms a generic regimen at matched active concentrations.

Adverse effects and their management#

Cosmetic and peel reactions

Retinoids and acid peels can cause irritation, erythema, dryness, peeling and pigment change. The 251-person combination series reported adverse events in 3.2%, but product-specific attribution is impossible because lasers and topicals were combined.[9]

Prescription-system risks

Hydroquinone-containing systems have documented pigmentary harm, including reports of depigmentation and paradoxical hyperpigmentation. Prescription monitoring and duration are prescriber matters.[13]

Escalation

Persistent inflammation, blistering, delayed healing, infection, progressive pigment change, suspected ochronosis or systemic symptoms requires cessation and medical assessment. The record should preserve the exact market version, ingredients, prescriber, product, lot and concurrent procedure.

Referral and scope boundaries#

Hydroquinone and tretinoin belong to an authorised prescriber. A client requesting a US ZO prescription product is referred rather than sold a substitute under the same brand name.[1, 2, 3, 6]

Moderate-to-severe acne, scarring, suspected ochronosis, atypical pigmentation, changing lesions, dermatitis or a significant peel reaction requires appropriate clinical referral. A brand programme does not replace diagnosis.

Mechanism of action#

ZO products use several established active classes: cosmetic retinoids, salicylic and other peel acids, antioxidants and, in US prescription ranges, hydroquinone and tretinoin. Their mechanisms belong to the relevant ingredient and treatment evidence, not to the brand claim.

A combination programme can act through several pathways at once, but that does not identify which component caused an observed change. The Japanese studies' lasers, oral tranexamic acid, tretinoin, hydroquinone and supporting topicals are therefore a package, not a ZO mechanism test.[9, 14]

Commonly misstated claims#

“ZO is the newer Obagi line, so Nu-Derm research applies”

The companies are legally separate and litigated against each other. Nu-Derm is an Obagi Medical product.[5, 11, 12]

Supported statement: ZO was founded by Dr Obagi after Obagi Medical, but their product evidence is not interchangeable.

“ZO is prescription-strength skincare available from UK clinics”

ZO's archived US range contained Rx hydroquinone and tretinoin; the UK range is cosmetic and retinol-based.[6, 7]

Supported statement: UK ZO products are cosmetics; prescription products require lawful UK prescribing and supply.

“Hydroquinone is simply banned in the UK”

It is prohibited in GB cosmetics, not categorically as a medicine. No licensed hydroquinone medicine is listed, so clinical access means an unlicensed prescription.[1, 2, 3]

Supported statement: hydroquinone skin cream is not lawful cosmetic retail and any medicinal use is a prescriber-led unlicensed route.

“The ZO 3-Step Peel contains hydroquinone”

The published three-component lists contain salicylic, TCA and lactic acids, retinol and supporting ingredients, but no hydroquinone.[6]

Supported statement: 3-Step Peel is an acid-and-retinol professional peel system.

Areas of remaining uncertainty#

  • Current US availability of the archived 4% hydroquinone items was not verified; this prevents describing them as present-day SKUs.
  • The 2026 acne study does not name a marketed product in its abstract; this prevents assigning its results to a specific ZO formula.
  • The precise ZO products used in the largest Japanese series are not named; this prevents formula-level attribution.
  • UK and US products sharing a name may differ; this means the current UK pack, not foreign marketing, governs.
  • No active-controlled ZO formulation trial was located; this prevents claims of superiority over matched generic skincare.

Frequently asked questions#

Is ZO the same company as Obagi Medical?

No. They are separate companies and their studies are not interchangeable.[5]

Can a UK aesthetician supply ZO 4% hydroquinone?

No. Hydroquinone skin cream cannot be a GB cosmetic, and medicinal supply requires a named prescriber accepting unlicensed-product responsibility.[1, 2, 3]i

Is ZO tretinoin available as UK retail skincare?

No. Tretinoin is prescription-only; the UK ZO catalogue is cosmetic and retinol-based.[2, 3, 7]

Does the 3-Step Peel contain hydroquinone?

Not in the published ingredient lists.[6]

What ZO protocol applies?

The current instructions for the exact UK product govern. Skinipedia does not publish a generic brand protocol.

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (assimilated law as it applies in Great Britain), Annex II (list of substances prohibited in cosmetic products) and Annex III (restricted substances). legislation.gov.uk.Tier 1Supports: Annex II reference 1339 reads verbatim: '1,4-Dihydroxybenzene (Hydroquinone), with the exception of entry 14 in Annex III', CAS 123-31-9, EC 204-617-8. Annex III entry 14 permits hydroquinone only in 'Artificial nail systems' at '0,02 % (after mixing for use)', 'Professional use only', with mandatory labelling 'For professional use only / Avoid skin contact / Read directions for use carefully'. Scope limit: this is cosmetics law only. It says nothing about hydroquinone supplied as a medicine, and it is GB law — Northern Ireland follows the EU regulation directly.
  2. The Human Medicines Regulations 2012 (SI 2012/1916), regulation 214 (sale, supply and administration of prescription only medicines). legislation.gov.uk.Tier 1Supports: Verbatim: '(1) A person may not sell or supply a prescription only medicine except in accordance with a prescription given by an appropriate practitioner.' Regulation 214(3) lists appropriate practitioners as: a doctor; a dentist; a supplementary prescriber; a nurse independent prescriber; and a pharmacist independent prescriber. Further paragraphs add community practitioner nurse prescribers (214(4), limited to Schedule 13), optometrist independent prescribers (214(5), with exclusions), podiatrist independent prescribers (214(5A)), physiotherapist independent prescribers (214(5B)), therapeutic radiographer independent prescribers (214(5C)) and paramedic independent prescribers (214(5D)), each with listed controlled-drug exclusions, plus approved country health professionals (214(6)). Scope limit: the regulation sets who may prescribe and supply; it does not itself classify tretinoin — classification comes from the product's marketing authorisation or, for unlicensed products, from the prescriber's clinical responsibility.
  3. UK electronic medicines compendium (emc, Datapharm) records for 'hydroquinone' and the active ingredient tretinoin. Accessed 1–2 August 2026.Tier 4Supports: A site search for 'hydroquinone' returns 'No search results for hydroquinone' — zero UK medicines listed. The tretinoin active-ingredient page lists three products: Aknemycin Plus (Almirall; erythromycin + tretinoin), Treclin 1%/0.025% w/w Gel (Viatris; tretinoin + clindamycin phosphate) and Tretinoin 10mg soft capsules (Neon Healthcare; oral). No single-agent topical tretinoin cream is listed. Scope limits: the emc is an industry-populated database of SPCs and PILs, not the statutory MHRA register, and inclusion is voluntary, so absence is strong but not conclusive proof that no UK marketing authorisation exists. The MHRA Products database (products.mhra.gov.uk) could not be queried because it renders results via JavaScript and returned an empty template to automated fetchers.
  4. Companies House register entry for ZO SKIN HEALTH LIMITED, company number 13395730 (overview, officers and persons with significant control). Find and update company information service.Tier 4Supports: Private limited company, incorporated in England and Wales 14 May 2021, active, SIC 86210 (general medical practice activities), registered office 20 Eastbourne Terrace, London W2 6LG; previous name WIGMORE AESTHETICS LIMITED until 14 September 2021. Accounts last made up to 31 December 2024. PSC register: ZO SH HOLDINGS INC, a Delaware (US) corporation, recorded with ownership of shares of 75% or more, notified and ceased 22 October 2025, with the current position an active statement that the company believes there is no registrable person; two earlier individual PSCs (Bedros Loutfig Eghiayan and Michael Avedissian, each >25%–50%) ceased 5 August 2021. Current directors Tanya Louise Hayden and Peter Justin Skala (both American, resident US, appointed 1 April 2024). Scope limit: the register shows corporate control, not commercial distribution agreements; it does not establish which entities physically import or wholesale ZO stock into UK clinics.
  5. Obagi Medical Products, Inc. Annual Report on Form 10-K for the fiscal year ended 31 December 2012 (SEC filing), Item 1 Business, Item 3 Legal Proceedings, and Notes 9 and 10 to the Consolidated Financial Statements.Tier 4Supports: Corporate history: 'The Company was founded as WorldWide Product Distribution, Inc. ("Worldwide") in 1988'; renamed Obagi Medical Products, Inc. in December 1997; 'Our leading product line, launched in 1988, is the Obagi Nu-Derm System.' Portfolio described as including 'cosmetic, OTC and prescription products, including 4% hydroquinone', sold through physician offices; net sales $120.7m in 2012. Separation: Obagi Medical terminated the 2006 Services Agreement with the Dr Obagi parties effective 4 October 2010, and 'As of November 30, 2010, Zein Obagi, M.D., the Company's former executive medical director and board member, ceased to own any shares of the Company's common stock.' Litigation: 'On January 7, 2010, ZO Skin Health, Inc., a California corporation, filed a complaint in the Superior Court of the State of California, County of Los Angeles: ZO Skin Health, Inc. vs. OMP, Inc. and Obagi Medical Products, Inc. and Does 1-25; Case No. BC429414', with a parallel JAMS arbitration demand by Zein and Samar Obagi and related entities. Settlement: 'On May 2, 2011, we entered into the Settlement Agreement with the ZO Parties … that resulted in the dismissal with prejudice of all claims and counterclaims', providing '(i) a one-time payment of $5.0 million from us to the ZO Parties; and (ii) the grant of a limited, non-exclusive license by us to the ZO Parties to use certain of our trademarks in up to three locations'; $5.0m plus $2.9m of litigation fees expensed in FY2011; other non-economic terms confidential. Scope limit: this is Obagi Medical's account of a dispute with ZO, filed by one side.Funding / interest: SEC filing by Obagi Medical Products, Inc., the commercial counterparty and litigation opponent of ZO Skin Health, Inc. Statements about the dispute are that company's own characterisation.
  6. ZO Skin Health, Inc. US product pages, retrieved from the Internet Archive: 'Pigment Control Program + Hydroquinone' (zoskinhealth.com/collections/programs-kits/products/pigment-control-program-hydroquinone, snapshot 4 July 2022), 'TRETINOIN' ZO Medical product page (zoskinhealth.com/product/tretinoin, snapshot 12 May 2012), and 'ZO 3-Step Peel' professional treatment page (zoskinhealth.com/collections/professional-treatments/products/zo-3-step-peel, snapshot 5 July 2022).Tier 4Supports: Pigment Control Program + Hydroquinone, $182 USD, Shopify product type 'Professional Treatment', SKU 915200, tagged 'badge:Rx'; six-product regimen comprising Gentle Cleanser, Exfoliating Polish, Complexion Renewal Pads, Daily Power Defense, 'Pigment Control Crème 4% HQ - RX' and 'Pigment Control + Blending Crème 4% HQ - RX'. Correction on re-checking: the words 'Prescription only' do NOT appear anywhere on the 4 July 2022 Pigment Control snapshot — its prescription status is carried by the 'RX' in the two hydroquinone SKU names, the 'badge:Rx' tag and dosing text reading 'twice a day or as directed by a physician'. The verbatim 'Prescription only.' belongs to the separate ZO Medical tretinoin page, which states in full: 'Tretinoin USP available in 0.1% and 0.05% cream in 20 g tubes. Only available though a physician. Prescription only.' (typo 'though' is in the original). ZO 3-Step Peel: 'For Professional Use Only. The procedure for and use of ZO 3-Step Peel can only be performed by a licensed physician or, if permitted by law, a properly trained specialist working under a physician's supervision.' Its published ingredient lists are — Peel Solution: Alcohol Denat., Salicylic Acid, Trichloroacetic Acid, Lactic Acid, Aqua, Ethoxydiglycol, Yellow 5; Retinol Crème Complex: aqueous emulsion containing Retinol plus botanicals, tocopheryl acetate, ascorbic acid, ubiquinone; Hydrating Crème: Aqua, Glycerin, Petrolatum … Tocopheryl Acetate, Retinyl Palmitate, Ascorbic Acid, Tetrapeptide-21, Myristoyl Pentapeptide-11. No hydroquinone appears in any of the three 3-Step Peel ingredient lists. Scope limits: these are archived US pages (2012–2022), not the live 2026 US catalogue, and they describe the US market only.Funding / interest: ZO Skin Health, Inc.'s own commercial marketing and e-commerce material. Product descriptions and ingredient lists are manufacturer statements, not independently verified.
  7. ZO Skin Health UK consumer website (zoskinhealth.co.uk), homepage and navigation, retrieved from the Internet Archive snapshot of 2 January 2026.Tier 4Supports: Site footer states '© 2026 ZO Skin Health, Inc. All Rights Reserved This site is intended for U.K. Consumers'; schema.org Organization name 'ZO Skin Health Marketing UK'; Salesforce Commerce site id 'Sites-ZOSkinHealth-Mar-UK-Site', locale en_GB. Product navigation categories are Cleansers, Exfoliators, Toners, Retinols, Targeted Treatments, Peels + Masques, Sunscreens, Eye Care, Hydrators, Body Care; solution categories are Anti-Aging, Brightening, Redness, Hydration, Sensitive Skin, Sun Protection. The strings 'prescription', 'hydroquinone' and 'tretinoin' do not occur anywhere in the snapshot. The site sells direct to consumers with a 'Choose My Partner' provider option and states 'ZO products are available exclusively through our official ZO website and authorized providers. Purchasing from unauthorized sellers increases the risk of counterfeit products'. Brand positioned as 'the leading Physician-Dispensed Skincare Brand Founded by Dr. Zein Obagi', footnoted 'Source: Guidepoint Qsight - Sales Measurement - Professional-Grade Skincare as of 1/7/2025. Qsight Sales Measurement data is based on point-of-sale transactions from 3,400+ US Aesthetics practice locations' — a US dataset, and the date 1/7/2025 is ambiguous between 7 January and 1 July on a UK-facing page. Scope limit: navigation categories are not a full SKU-by-SKU ingredient audit.Funding / interest: ZO Skin Health, Inc.'s own UK direct-to-consumer commerce site. All claims are the manufacturer's.
  8. ZO Skin Health, Inc. press release, 'Global Advisor, Colleen Goggins, Joins ZO Skin Health's Board of Directors Following Majority Investment By Blackstone', PR Newswire, 3 December 2020.Tier 4Supports: States that ZO Skin Health was founded in 2007 by dermatologist Dr Zein Obagi; that Blackstone acquired a majority stake in October 2020; and describes ZO as 'a premium California-based skincare brand sold internationally through physicians and skincare professionals'. Boilerplate: ZO 'develops and delivers innovative skincare solutions … By providing comprehensive skincare programs for physicians and their patients, ZO bridges the gap between therapeutic treatments and daily care'. Scope limit: corporate promotional copy; deal terms were not disclosed, and this predates any 2021–2026 ownership changes. The Blackstone press release itself could not be retrieved directly (Cloudflare challenge).Funding / interest: Company-issued press release distributed by ZO Skin Health, Inc.; Blackstone is the acquiring investor.
  9. Takekawa C, Fukumoto T, Haraoka G, Terashi H. Combination treatment algorithm for pigmentary disorders of the face: a prospective observational study in Asian patients. J Plast Reconstr Aesthet Surg. 2021 Feb;74(2):370–376.Tier 3Supports: Prospective observational study, no control group. 251 patients enrolled and 227 completed treatment (the figure 246 in the abstract is the number with lentigo senilis, not the number completing); all Asian, study conducted in Japan. Diagnoses overlapped: lentigo senilis 246, moles 186, melasma 79, seborrhoeic keratosis 53, acquired dermal melanocytosis 17, freckles 16. Protocol combined Q-switched alexandrite and carbon dioxide lasers 'with ZO SKIN HEALTH®'. Outcomes by categorical rating in the 227 completers: excellent 97, good 113, fair 17, poor 0. Adverse events 3.2%. Freckles most responsive, acquired dermal melanocytosis least; patient withdrawal and outcomes did not differ significantly by doctors' skill level. Scope limits: single-country, single-ethnicity cohort; no randomisation, no comparator and no arm using the topicals alone, so the ZO products' independent contribution cannot be separated from two laser modalities; outcome scale is subjective and not blinded in the abstract; which specific ZO products (and whether any contained hydroquinone) is not stated in the abstract — though a later paper by the same first author (source 14) describes the ZO programme used in that setting as hydroquinone-based. No funding or conflict-of-interest statement was retrievable from the PubMed record; the full text is paywalled. DOI 10.1016/j.bjps.2020.08.131.
  10. Hornby SB, Ly YH, Obagi ZA, Obagi ZE, Stahl CC, Woodin FW Jr. A Novel Retinoid and Salicylic Acid Topical Treatment for Moderate-Severe Acne. J Drugs Dermatol. 2026 Jun 1;25(6):558–561.Tier 3Supports: 12-week study (DOI 10.36849/JDD.9390) of 'a retinol plus site-specific salicylic acid-targeted bio-delivery system' in 40 patients with moderate-to-severe acne, Fitzpatrick skin types I–VI. Investigator grading: 27.8% reduction in inflamed pustules at 2 weeks and 68.6% at 12 weeks; nodules improved 61.1% at 2 weeks and 92.2% at 12 weeks; post-inflammatory hyperpigmentation improved 32.3% at 12 weeks; microbiome analysis showed a 52% reduction in Cutibacterium acnes by week 12; no erythema by week 12 and no oedema throughout; patients reported no significant itching, burning, tingling or stinging. Scope limits: the abstract describes no randomisation, no control or comparator arm and no blinding, so the effect sizes are uncontrolled within-group changes; no commercial brand or SKU is named in the abstract, so the link to a marketed ZO product is by authorship and formulation description, not by statement; n=40 is small for skin-type subgroup claims.Funding / interest: The author list includes Zein E. Obagi, founder of ZO Skin Health, Inc., and Zaidal A. Obagi. Published in a journal that carries substantial aesthetics-industry content. No funding or disclosure statement was retrievable — the PubMed record carries none and the publisher's full text was not accessible (404 on the article URL tried). Treat as manufacturer-affiliated until the disclosure statement can be read.
  11. Pannucci CJ, Reavey PL, Kaweski S, Hamill JB, Hume KM, Wilkins EG, Pusic AL. A randomized controlled trial of skin care protocols for facial resurfacing: lessons learned from the Plastic Surgery Educational Foundation's Skin Products Assessment Research study. Plast Reconstr Surg. 2011 Mar;127(3):1334–1342. PMCID PMC3079206.Tier 2Supports: Multicentre, double-blind, randomised controlled trial in women with Fitzpatrick I–IV skin, moderate-to-severe facial photodamage and periocular and/or perioral fine wrinkles undergoing chemical peel or laser resurfacing. 56 women enrolled; 46 completed (24 Obagi Nu-Derm System, 22 control), 82% followed beyond re-epithelialisation. Randomised to the Obagi Nu-Derm System versus a standard care regimen. Results: mean time to re-epithelialisation 6.6 days (Nu-Derm) versus 7.3 days (control), p=0.63 — 'no significant differences in mean time to reepithelialization between Obagi Nu-Derm System and control groups'; 'no significant differences between groups in levels of hyper or hypo-pigmentation'. The Nu-Derm group had a significantly higher median erythema score on the day of surgery after four weeks of pre-treatment (p=0.009, mild versus none), which the authors themselves said 'may not be clinically relevant for most patients or providers', and 'no significant differences in post-procedure erythema score were noted at any time point'. Scope limits: this tests Obagi Medical's Nu-Derm system, NOT a ZO Skin Health product; small sample; endpoints were healing and erythema/pigment change around resurfacing, not long-term photoageing outcomes; a 46-completer study cannot exclude a modest real effect.Funding / interest: Disclosed in the paper: 'Unrestricted grant from Obagi Medical Products to the Plastic Surgery Educational Foundation. Obagi Medical Products was not involved in any aspect of study design, data collection, or data analysis.' No authors reported financial interests in the products studied. Note the direction: the null result went against the sponsor's own product, which makes it more credible, not less. The stated aim also included developing 'an infrastructure for Plastic Surgery Educational Foundation-conducted, industry-sponsored research in facial aesthetic surgery'.
  12. Fabi SG, Goldman MP. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging. J Drugs Dermatol. 2013 Mar;12(3):S32–37.Tier 2Supports: Investigator-blinded randomised trial comparing the 4-product hydroquinone-free SkinMedica Hyperpigmentation System against the 7-product hydroquinone-containing Obagi Nu-Derm System in women with mottled pigmentation and photodamaged facial skin, assessed at baseline and weeks 4, 8 and 12. 36 female subjects completed (16 SkinMedica, 20 Obagi). Both regimens significantly reduced Overall Hyperpigmentation, Mottled Pigmentation Area and Severity Index (MoPASI), global photoageing and sallowness at week 12 versus baseline; 'Significant reductions in tactile roughness were seen with the OMP regimen at week 12' — i.e. the hydroquinone arm did beat the comparator on that one endpoint. Verbatim: 'In these investigator-blinded assessments, there were no significant differences between treatment groups, nor was there a difference in global response to treatment.' Tolerability mean scores mild or below in both arms. Scope limits: neither product is a ZO Skin Health product; small n with unequal groups; 12 weeks only; a 36-subject study is underpowered to exclude a modest real difference, so 'no significant difference' is not proof of equivalence.Funding / interest: Published in a Journal of Drugs in Dermatology supplement issue. The paper itself identifies the hydroquinone-free comparator as 'SkinMedica® Hyperpigmentation System (SKM; SkinMedica, an Allergan Company, Carlsbad, CA)'. The Europe PMC core record carries no grants list and no conflict-of-interest field, and the full text was not accessible, so sponsorship could not be confirmed either way. Read the result knowing the framing — 'as effective and tolerable as' — favours the SkinMedica product, and that both named authors are San Diego cosmetic dermatologists who publish frequently on Allergan/SkinMedica products.
  13. Jow T, Hantash BM. Hydroquinone-induced depigmentation: case report and review of the literature. Dermatitis. 2014 Jan-Feb;25(1):e1–5.Tier 3Supports: Case report of two patients (n=2) with Fitzpatrick skin type III/IV who developed depigmentation and paradoxical hyperpigmentation after brief treatment of melasma with the hydroquinone-containing Nu-Derm and Reverse systems; the abstract states this was described 'for the first time' in type III/IV skin, previous reports having suggested the risk of leukoderma from hydroquinone was limited to individuals of African descent. The accompanying narrative review covers hydroquinone adverse effects ranging from irritant contact dermatitis to exogenous ochronosis. Scope limits: n=2, uncontrolled, causality inferred from timing; the products are Obagi Medical's, not ZO's; a case report plus narrative review establishes that a harm can occur, not how often. No funding or conflict-of-interest statement was retrievable from the PubMed record.
  14. Kitano D, Morita M, Takekawa C. Safe and Effective Treatment Protocol for Facial Pigmentary Disorders in Asian Patients: A Key to Success for Plastic Surgery Residents With Limited Clinical Experience in Aesthetic Dermatology. Cureus. 2025 May;17(5):e83467. PMCID PMC12133205.Tier 3Supports: Retrospective observational study of 27 consecutive Asian patients seen at a Japanese clinic between December 2020 and December 2021; 6 patients with 'aging complex pigmentation' completed the full combination therapy. Protocol combined oral tranexamic acid 1,000 mg/day, vitamin C 1,000 mg/day and vitamin E 50 mg/day with, verbatim, 'daily chemical bleaching using ZO® (ZO Skin Health Inc., Irvine, California, United States)' — patients applying 'Milamin® in the morning and Miramix® in the evening for the first week, both of which are HQ-based formulations', then adding '0.1% RA ointment (Obagi® Tretinoin 0.1% Cream, Obagi Cosmeceuticals LLC, Long Beach, California, United States)'. Q-switched laser was given at week six of the ZO programme. Mean MASI fell from 19 before treatment to 2.8 after (p=0.0054, unpaired t-test), graded blind by two board-certified attending physicians. Scope limits: retrospective, no control group, only 6 completers of the combination therapy, and the ZO topicals were delivered alongside three oral agents, a separate tretinoin product and a laser, so no independent effect can be attributed to them; the ZO products named are the hydroquinone-based ones, which cannot lawfully be GB cosmetics. The paper's own framing is a training-of-residents question, not a product-efficacy question.Funding / interest: ICMJE disclosure printed in the paper: 'All authors have declared that no financial support was received from any organization for the submitted work'; no financial relationships within the previous three years; no other relationships. Chikara Takekawa is also first author of the 251-patient JPRAS series (source 9), so the two ZO-naming clinical papers share an author and a clinical setting.
  15. Europe PMC and NCBI PubMed records for "ZO Skin Health", "ZO Skin Health"[All Fields] AND randomized, Obagi ZE[Author] and Obagi ZA[Author]. Accessed 2 August 2026.Tier 4Supports: The Europe PMC phrase search returns hitCount 6: Takekawa 2021 (JPRAS, source 9); Kitano 2025 (Cureus, source 14); a 2015 book review of The Art of Skin Health in Aesthetic Surgery Journal; and three papers where the brand appears incidentally (two preservation-rhinoplasty roundtables in Aesthetic Surgery Journal Open Forum, one cellulite-severity-scale comparison). Two of the six are therefore clinical studies that used ZO products; neither is randomised or controlled. Obagi ZE[Author] returns 5 records, the most recent being PMID 42235053 (source 10); Obagi ZA[Author] returns 2. '"ZO Skin Health"[All Fields] AND randomized' returns 0. Scope limits: PubMed does not hold 'ZO Skin Health' in its phrase index, so a quoted PubMed search is term-mapped and returns 91 loosely related records — it is not a zero-result search, and Europe PMC full text is the reliable route. Absence from these indexes is not proof that no trial exists anywhere, only that none is indexed.